Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

To see how effective the study medicine combined with hormone therapy is when given to participants with recurrent low-grade serous ovarian cancer.

Trial Details

NCT ID
NCT05113368
Phase
PHASE2
Sponsor
Sarah K. Lynam MD
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Regorafenib
  • Fulvestrant
Locations (sample)
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • Subjects must have recurrent low-grade serous ovarian cancer.
  • Up to 5 prior lines of therapy are allowed.
  • Prior therapy with MEK inhibitors is allowed
  • Prior therapy with aromatase inhibitors like letrozole is allowed

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →